Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492059 | 1.00 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6670333 | 0.86 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6964610 | 0.86 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3450089 | 0.84 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL83699 | 0.81 | CA2 (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL57432 | 0.81 | CA2 (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL90052 | 0.81 | CA2 (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL873398 | 0.79 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL206502 | 0.79 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL873787 | 0.79 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859812-B2 | Compound reagents and method for synthesizing enantiomerically enriched amino acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2011031764-A2 | COMPOUNDS AND RELATED METHODS OF USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | BCAT2, BCAT1, AADAT | CTSK 1150/4885CTSS 1849/4885CA1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.